Vertex Pharmaceuticals, Inc [VRTX] stock prices are up 1.35% to $467.35 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VRTX shares have gain 3.96% over the last week, with a monthly amount glided 2.44%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] stock has seen the most recent analyst activity on January 22, 2026, when RBC Capital Mkts upgraded its rating to an Outperform but kept the price target unchanged to $546 for it. Previously, Bernstein upgraded its rating to Outperform on January 12, 2026. Wolfe Research upgraded its rating to an Outperform but stick to its price target of $548 on January 06, 2026. Morgan Stanley upgraded its rating to an Overweight but $516 remained the price target by the analyst firm on December 03, 2025. Scotiabank started tracking with a Sector Outperform rating for this stock on November 13, 2025, and assigned it a price target of $495. In a note dated September 25, 2025, Leerink Partners upgraded an Outperform rating on this stock but restated the target price of $456.
The stock price of Vertex Pharmaceuticals, Inc [VRTX] has been fluctuating between $362.50 and $519.68 over the past year. Currently, Wall Street analysts expect the stock to reach $501.2 within the next 12 months. Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] shares were valued at $467.35 at the most recent close of the market. An investor can expect a potential return of 7.24% based on the average VRTX price forecast.
Analyzing the VRTX fundamentals
The Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] reported sales of 11.73B for trailing twelve months, representing a surge of 12.27%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at 0.34%, Pretax Profit Margin comes in at 0.38%, and Net Profit Margin reading is 0.31%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.22 and Total Capital is 0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Vertex Pharmaceuticals, Inc [NASDAQ:VRTX]’s Current Ratio is 2.36. As well, the Quick Ratio is 2.00, while the Cash Ratio is 1.1. Considering the valuation of this stock, the price to sales ratio is 10.10, the price to book ratio is 6.85 and price to earnings (TTM) ratio is 32.94.
Transactions by insiders
Recent insider trading involved Tatsis Ourania, EVP, Chief Reg. & Quality Off., that happened on Jan 07 ’26 when 4500.0 shares were sold. EVP, CO & FO, WAGNER CHARLES F JR completed a deal on Jan 06 ’26 to sell 9532.0 shares. Meanwhile, Officer Tatsis Ourania bought 4500.0 shares on Jan 07 ’26.
